Life sciences news
-
UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis
Friday December 10th 2021
Read more
-
MRM Health announces first patient dosed with next generation live microbiome consortia therapeutic MH002 in Phase 1b/2a study in patients with Ulcerative Colitis
Wednesday December 8th 2021
Read more
-
Sequana Medical announces the completion of patient enrolment in POSEIDON, the North American pivotal alfapump® study
Tuesday December 7th 2021
Read more
-
Sequana Medical announces positive interim results of SAHARA DESERT, the alfapump DSR® study in heart failure patients with persistent congestion
Tuesday December 7th 2021
Read more
-
S-Biomedic announces topline results of a successful clinical study in acne
Friday November 26th 2021
Read more
-
Galapagos completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease
Tuesday November 23rd 2021
Read more
-
OXURION NV - First patient dosed in Part B of Phase 2 KALAHARI study evaluating multiple administrations of THR-149 versus aflibercept for treatment of Diabetic Macular Edema (DME)
Monday November 15th 2021
Read more
-
Oxurion NV announces first patient dosed in its Phase 2 Study evaluating THR-687 for the treatment of Diabetic Macular Edema (DME)
Wednesday October 13th 2021
Read more
-
Become a flanders.bio member
Your news here?
-
Precirix dosed first patients in Phase I/II clinical study evaluating CAM-H2 in HER2-positive metastatic cancer
Wednesday October 6th 2021
Read more
-
Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease
Monday October 4th 2021
Read more
-
Sequana Medical announces FDA approval to expand patient enrolment in North American pivotal alfapump® study (POSEIDON)
Monday October 4th 2021
Read more
More info?
Contact us
Ellen Telleir
Communication Coordinator
